IISc researchers combine antibiotics to tackle drug-resistant TB

Bacteria which cause tuberculosis Mycobacterium tuberculosis, 3D illustration
Researchers at the Indian Institute of Science (IISc), have identified a strategy to restore the effectiveness of isoniazid, a frontline drug used to treat tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis (M. tuberculosis).
According to the IISc, TB caused by M. tuberculosis, continues to remain one of the world’s most persistent health challenges. However, it said that what’s particularly alarming is the bacterium’s growing resistance to isoniazid.
Now, researchers at the Department of Biochemistry have now identified a strategy to restore the effectiveness of isoniazid – by combining it with another antibiotic, vancomycin.
They found that this combination can reverse isoniazid resistance in clinical isolates of M. tuberculosis and reduce bacterial burden in a mouse model.
“Isoniazid resistance poses a major challenge in the treatment of TB. To tackle this problem, we started exploring ways to rescue the drug by reversing resistance,” said Nagasuma Chandra, Professor at the Department of Biochemistry and corresponding author of the study published in Microbiology Spectrum.
PhD student and first author of the study, Sukriti Pal said that although several antibiotic combinations are available for TB treatment challenges presist due to drug-resistance.
She said that the new study identifies a drug treatment strategy that can reverse resistance to isoniazid, an otherwise highly effective antibiotic.
The researchers tested the combination of isoniazid and vancomycin against clinical isolates of M. tuberculosis obtained from patient sputum samples with drug-resistant TB, in collaboration with the National Tuberculosis Institute, Bengaluru. The isolates showed a broad range of isoniazid resistance, which allowed the researchers to test the combination against various resistance mechanisms.
IISc said that isoniazid is a prodrug which requires activation by a bacterial enzyme to be effective.
However, mutations in specific genes can create resistant bacteria that block this activation pathway. Likewise, vancomycin has difficulty penetrating the impermeable cell wall in M. tuberculosis. When used together, a loss of cell wall integrity allows vancomycin to enter the cell and start killing the bacteria.
“The combination substantially reduced bacterial burden compared to the individual drugs. Most of the isolates showed more than 90% reduction in bacterial growth under the combination treatment. This included isolates resistant to isoniazid as well as multidrug-resistant (MDR) isolates,” IISc said.
The researchers then tested the drug combination in a mouse model infected with an MDR M. tuberculosis in collaboration with Amit Singh, Professor at the Centre for Infectious Disease Research (CIDR) and Department of Microbiology and Cell Biology (MCB), IISc. After 10 days of treatment, neither isoniazid nor vancomycin alone produced a significant reduction in bacterial burden. However, the combination resulted in an approximately 10-fold reduction in bacterial load both in the lungs and spleen.
Histopathological examination revealed that the combination treatment lowered the number of lung granulomas. The team is currently working to advance this combination for clinical trials.
- iisc
- researcher
- antibiotic
- drug




